Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models

Journal of Toxicological Sciences

Volumn 37, Issue 5, 2012, Pages 931-942

  Miyashita, Taishi ^a   Toyoda, Yasuyuki ^a   Tsuneyama, Koichi ^b   Fukami, Tatsuki ^a   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

ERK; NASH; Steatosis; Tamoxifen

Indexed keywords

ACYL COENZYME A; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHEMOKINE; CYTOKINE; DIACYLGLYCEROL ACYLTRANSFERASE 2; INITIATION FACTOR 2ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; TAMOXIFEN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; ENZYME PHOSPHORYLATION; FATTY LIVER; FEMALE; GENE EXPRESSION; HEPATITIS; LIPID STORAGE; LIVER INJURY; LIVER PROTECTION; LIVER REGENERATION; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN;

EID: 84867861053     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.37.931     Document Type: Article

References (47)

1. Alvaro, D., Onori, P., Metalli, V.D., Svegliati-Baroni, G., Folli, F., Franchitto, A., Alpini, G., Mancino, M.G., Attili, A.F. and Gaudio, E. (2002): Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat. Hepatology, 36, 297-304.
2. Angulo, P. (2002): Nonalcoholic fatty liver disease. N. Engl. J. Med., 346, 1221-1231.
3. Anstee, Q.M. and Goldin, R.D. (2006): Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol., 87, 1-16.
4. Caballero, F., Fernandez, A., Matias, N., Martinez, L., Fucho, R., Elena, M., Caballeria, J., Morales, A., Fernandez-Checa, J.C. and Garcia-Ruiz, C. (2010): Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione. J. Biol. Chem., 285, 18528-18536.
5. Choi, C.S., Savage, D.B., Kulkarni, A., Yu, X.X., Liu, Z.X., Morino, K., Kim, S., Distefano, A., Samuel, V.T., Neschen, S., Zhang, D., Wang, A., Zhang, X.M., Kahn, M., Cline, G.W., Pandey, S.K., Geisler, J.S., Bhanot, S., Monia, B.P. and Shulman, G.I. (2007): Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses dietinduced hepatic steatosis and insulin resistance. J. Biol. Chem., 282, 22678-22688.
6. Chow, J.D., Jones, M.E., Prelle, K., Simpson, E.R. and Boon, W.C. (2011): A selective estrogen receptor α agonist ameliorates hepatic steatosis in the male aromatase knockout mouse. J. Endocrinol., 210, 323-334.
7. Chowdhry, S., Nazmy, M.H., Meakin, P.J., Dinkova-Kostova, A.T., Walsh, S.V., Tsujita, T., Dillon, J.F., Ashford, M.L. and Hayes, J.D. (2010): Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic. Biol. Med., 48, 357-371.
8. Cole, L.K., Jacobs, R.L. and Vnace, D.E. (2010): Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology, 52, 1258-1265.
9. Cosman, F. and Lindsay, R. (1999): Selective estrogen receptor modulators: clinical spectrum. Endocr. Rev., 20, 418-434.
10. Czaja, M.J., Liu, H. and Wang, Y. (2003): Oxidant-induced hepatocyte injury from menadione is regulated by ERK and AP-1 signaling. Hepatology, 37, 1405-1413.
11. Dhingra, K. (1999): Antiestrogens-tamoxifen, SERMs and beyond. Invest. New Drugs, 17, 285-311.
12. Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D. and Parks, E.J. (2005): Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest., 115, 1343-1351.
13. Haque, J.A., McMahan, R.S., Campbell, J.S., Shimizu-Albergine, M., Wilson, A.M., Botta, D., Bammler, T.K., Beyer, R.P., Montine, T.J., Yeh, M.M., Kavanagh, T.J. and Fausto, N. (2010): Attenuated progression of diet-induced steatohepatitis in glutathione-deficient mice. Lab. Invest., 90, 1704-1717.
14. Harada, H., Bharwani, S., Pavlick, K.P., Korach, K.S. and Grisham, M.B. (2004): Estrogen receptor-α, sexual dimorphism and reduced-size liver ischemia and reperfusion injury in mice. Pediatr. Res., 55, 450-456.
15. Harding, H.P., Zhang, Y., Bertolotti, A., Zeng, H. and Ron, D. (2000): Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol. Cell, 5, 897-904.
16. Higuchi, S., Kobayashi, M., Yoshikawa, Y., Tsuneyama, K., Fukami, T., Nakajima, M. and Yokoi, T. (2011): IL-4 mediates dicloxacillin-induced liver injury in mice. Toxcol. Lett., 200, 139-145.
17. Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C.Z., Uysal, K.T., Maeda, K., Karin, M. and Hotamisligil, G.S. (2002): A central role for JNK in obesity and insulin resistance. Nature, 420, 333-336.
18. Hotamisligil, G.S. (2010): Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell, 140, 900-917.
19. Huang, H., He, J., Yuan, Y., Aoyagi, E., Takenaka, H., Itagaki, T., Sannomiya, K., Tamaki, K., Harada, N., Shono, M., Shimizu, I. and Takayama, T. (2008): Opposing effects of estradiol and progesterone on the oxidative stress-induced production of chemokine and proinflammatory cytokines in murine peritoneal macrophages. J. Med. Invest., 55, 133-141.
20. Jou, J., Choi, S.S. and Diehl, A.M. (2008): Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin. Liver Dis., 28, 370-379.
21. Kim, J.K., Fillmore, J.J., Chen, Y., Yu, C., Moore, I.K., Pypaert, M., Lutz, E.P., Kayo, Y., Velez-Carrasco, W., Goldberg, I.J., Breslow, J.L. and Shulman, G.I. (2001): Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. USA, 98, 7522-7527.
22. Kotzka, J. and Muller-Wieland, D. (2004): Sterol regulatory element-binding protein (SREBP)-1: gene regulatory target for insulin resistance? Expert Opin. Ther. Targets, 8, 141-149.
23. Kuiper, G.G., Carlsson, B., Grandien, K., Enmark, E., Haggblad, J., Nilsson, S. and Gustafsson, J.A. (1997): Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology, 138, 863-870.
24. Loomba, R., Sirlin, C.B., Schwimmer, J.B. and Lavine, J.E. (2009): Advances in pediatric nonalcoholic fatty liver disease. Hepatology, 50, 1282-1293.
25. Ludwig, J., Viggiano, T.R., McGill, D.B. and Oh, B.J. (1980): Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55, 434-438.
26. Malhi, H. and Kaufman, R.J. (2011): Endoplasmic reticulum stress in liver disease. J. Hepatol., 54, 795-809.
27. Maniratanachota, R., Minami, K., Katoh, M., Nakajima, M. and Yokoi, T. (2005): Chaperone proteins involved in troglitazoneinduced toxicity in human hepatoma cell lines. Toxicol. Sci., 83, 293-302.
28. Martindale, J.L. and Holbrook, N.J. (2002): Cellular response to oxidative stress: Signaling for suicide and survival. J. Cell Physiol., 192, 1-15.
29. Mitlak, B.H. and Cohen, F.J. (1997): In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm. Res., 48, 155-163.
30. Murata, Y., Ogawa, Y., Saibara, T., Nishioka, A., Fujiwara, Y., Fukumoto, M., Inomata, T., Enzan, H., Onishi, S. and Yoshida, S. (2000): Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol. Rep., 7, 1299-1304.
31. Naugler, W.E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A.M. and Karin, M. (2007): Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science, 317, 121-124.
32. Obsorne, C.K. and Fuqua, S.A. (1994): Mechanisms of tamoxifen resistance. Breast Cancer Res. Treat, 32, 49-55.
33. Ohoka, N., Yoshii, S., Hattori, T., Onozaki, K. and Hayashi, H. (2005): TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. EMBO J., 24, 1243-1255.
34. Okabe, H., Irita, K., Taniguchi, S., Kurosawa, K., Tagawa, K., Yoshitake, J. and Takahashi, S. (1994): Endotoxin causes early changes in glutathione concentrations in rabbit plasma and liver. J. Surg. Res., 57, 416-419.
35. Pessayre, D., Fromenty, B. and Mansouri, A. (2004): Mitochondrial injury in steatohepatitis. Eur. J. Gastroenterol. Hepatol., 16, 1095-1105.
36. Puri, P., Mirshahi, F., Cheung, O., Natarajan, R., Maher, J.W., Kellum, J.M. and Sanyal, A.J. (2008): Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology, 134, 568-576.
37. Riant, E., Waget, A., Cogo, H., Arnal, J.F., Burcelin, R. and Gourdy, P. (2009): Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology, 150, 2109-2117.
38. Seger, R. and Krebs, E.C. (1995): The MAPK signaling cascade. FASEB J., 9, 726-735.
39. Te Sligte, K., Bourass, K.I., Sels, J.P., Driessen, A., Stockbrugger, R.W. and Koek, G.H. (2004): Non-alcoholic steatohepatitis: Review of a growing medical problem. Eur. J. Intern. Med., 15, 10-21.
40. Tsai, J., Qiu, W., Kohen-Avramoglu, R. and Adeli, K. (2007): MEKERK inhibition corrects the defect in VLDL assembly in HepG2 cells: potential role of ERK in VLDL-ApoB100 particle assembly. Arterioscler Thromb. Vasc. Biol., 27, 211-218.
41. Tietze, F. (1969): Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal. Biochem., 27, 502-522.
42. Uesugi, T., Froh, M., Arteel, G.E., Bradford, B.U. and Thurman, R.G. (2001): Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology, 34, 101-108.
43. Ura, S., Masuyama, H., Graves, J.D. and Gotoh, Y. (2001): MST1-JNK promotes apoptosis via caspase-dependent and independent pathways. Genes Cells, 6, 519-530.
44. Vetelainen, R., van Vilet, A. and van Gulik, T.M. (2007): Essential pathogenic and metabolic differences in steatosis induced by choline or methione-choline deficient diets in a rat model. J. Gastroenterol. Hepatol., 22, 1526-1533.
45. Wang, Z., Yao, T. and Song, Z. (2010): Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease. J. Lipid Res., 51, 3158-3165.
46. Yoshikawa. Y., Miyashita. T., Higuchi. S., Tsuneyama. K., Endo. S., Tsukui. T., Toyoda. Y., Fukami. T., Nakajima. M. and Yokoi. T. (2012): Mechanisms of the hepatoprotective effects of tamoxifen against drug-induced and chemical-induced acute liver injuries. Toxicol. Appl. Pharmacol. In press.
47. Yu, X.X., Murray, S.F., Pandey, S.K., Booten, S.L., Bao, D., Song, X, Z., Kelly, S., Chen, S., McKay, R., Monia, B.P. and Bhanot, S. (2005): Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology, 42, 362-371.